Chimeric Therapeutics LimitedASX: CHM

Strategic manufacturing partnership with WuXi ATU

· Issued by Chimeric Therapeutics Limited

Filed with ASX · · 4 pages · English

Chimeric Therapeutics (ASX:CHM, “Chimeric”), a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that it has entered into a strategic manufacturing partnership with WuXi ATU, a global contract testing and manufacturing organization (CTDMO). Under the agreement, Chimeric will transfer certain manufacturing and analytical testing technologies to WuX

Chimeric Therapeutics Limited on 6ix

Earlier from Chimeric Therapeutics

Later from Chimeric Therapeutics

All Chimeric Therapeutics news releases